Should I buy or sell Absci stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Absci in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABSI shares. View ABSI analyst ratings or view top-rated stocks .

What is Absci's stock price target for 2024?

4 equities research analysts have issued 12 month target prices for Absci's shares. Their ABSI share price targets range from $7.00 to $13.00. On average, they expect the company's stock price to reach $9.25 in the next year. This suggests a possible upside of 71.9% from the stock's current price. View analysts price targets for ABSI or view top-rated stocks among Wall Street analysts .

How have ABSI shares performed in 2024?

Absci's stock was trading at $4.20 on January 1st, 2024. Since then, ABSI shares have increased by 28.1% and is now trading at $5.38. View the best growth stocks for 2024 here .

When is Absci's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ABSI earnings forecast .

How were Absci's earnings last quarter?

Absci Co. (NASDAQ:ABSI) announced its earnings results on Thursday, March, 21st. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.02. The company earned $0.34 million during the quarter, compared to analysts' expectations of $1.75 million. Absci had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 1,933.65%.

What ETF holds Absci's stock?

ARK Genomic Revolution ETF holds 3,164,891 shares of ABSI stock, representing 1.31% of its portfolio.

Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share.

Who are Absci's major shareholders?

Absci's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Salem Investment Counselors Inc. (0.02%). Insiders that own company stock include Karen K Mcginnis , Redmile Group, Llc, Sarah Korman , Sean Mcclain and Todd Bedrick . View institutional ownership trends .

How do I buy shares of Absci?

Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABSI

Absci (ABSI) Stock Price, News & Analysis

→ Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad)

Free ABSI Stock Alerts

$5.38

-0.05 (-0.92%)

(As of 04/16/2024 ET)

Compare

Today's Range: $5.24
▼
$5.49
50-Day Range: $3.97
▼
$6.59
52-Week Range: $1.11
▼
$6.72

Volume: 1.35 million shs
Average Volume: 1.55 million shs
Market Capitalization: $606.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.25

Get Absci alerts:

Absci MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 71.9% Upside
$9.25 Price Target
Short Interest: Bearish
13.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.99
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$999,999 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.76) to ($0.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.60 out of 5 stars

Medical Sector

520th out of 930 stocks

Commercial Physical Research Industry

9th out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
Absci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Absci has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
13.01% of the float of Absci has been sold short.
Short Interest Ratio / Days to Cover
Absci has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Absci has recently decreased by 1.87%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Absci does not currently pay a dividend.
Dividend Growth
Absci does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABSI.

2.8

News and Social Media Coverage

News Sentiment
Absci has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Absci this week, compared to 1 article on an average week.
Search Interest
Only 17 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
MarketBeat Follows
Only 21 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Absci insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,999.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
11.58% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Absci are expected to grow in the coming year, from ($0.76) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Absci is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Absci is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Absci has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

See who it is HERE.

About Absci Stock (NASDAQ:ABSI)

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ABSI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABSI Stock News Headlines

April 16, 2024 | finance.yahoo.com

Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024

March 28, 2024 | finance.yahoo.com

Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 23, 2024 | finance.yahoo.com

Absci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net Loss

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed for AbSci: Promising Pipeline and Strategic Partnerships Signal Growth

March 21, 2024 | benzinga.com

Absci: Q4 Earnings Insights

March 21, 2024 | investorplace.com

ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023

March 21, 2024 | globenewswire.com

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 13, 2024 | finance.yahoo.com

ABSI Apr 2024 6.000 call

March 7, 2024 | investing.com

Absci shares get buy rating, $9 target on AI biotech potential

March 1, 2024 | finance.yahoo.com

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

March 1, 2024 | globenewswire.com

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

February 28, 2024 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on AbSci (ABSI)

February 28, 2024 | msn.com

Why Absci (ABSI) Shares Are Falling

February 28, 2024 | msn.com

Absci prices $75M equity offering at $4.50 per share

February 27, 2024 | globenewswire.com

Absci Announces Pricing of Public Offering of Common Stock

February 27, 2024 | globenewswire.com

Absci Announces Proposed Public Offering of Common Stock

February 24, 2024 | ca.finance.yahoo.com

CNC Mar 2024 86.000 call

February 21, 2024 | finance.yahoo.com

Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?

February 21, 2024 | finance.yahoo.com

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

February 21, 2024 | globenewswire.com

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

February 16, 2024 | finance.yahoo.com

ABSI Mar 2024 7.500 call

February 16, 2024 | finance.yahoo.com

ABSI Feb 2024 7.500 put

February 5, 2024 | finance.yahoo.com

Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?

January 21, 2024 | finance.yahoo.com

Both retail investors who control a good portion of Absci Corporation (NASDAQ:ABSI) along with institutions must be dismayed after last week's 15% decrease

January 10, 2024 | finance.yahoo.com

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

See More Headlines

Receive ABSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Commercial physical research
Sub-Industry: N/A
Current Symbol: NASDAQ:ABSI
CUSIP: N/A
CIK: 1672688
Web: www.absci.com
Phone: 360-949-1041
Fax: N/A
Employees: 155
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.25
High Stock Price Target: $13.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +70.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-110,570,000.00
Net Margins: -1,933.65%
Pretax Margin: -1,931.90%
Return on Equity: -44.52%
Return on Assets: -37.35%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 4.08
Quick Ratio: 4.08

Sales & Book Value

Annual Sales: $5.72 million
Price / Sales: 107.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.90 per share
Price / Book: 2.86

Miscellaneous

Outstanding Shares: 112,790,000
Free Float: 99,724,000
Market Cap: $612.45 million
Optionable: Optionable
Beta: 2.36

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Sean McClain (Age 33)
Founder, CEO, President & Director
Comp: $936.2k
Dr. Zachariah Jonasson Ph.D. (Age 50)
Chief Business Officer & CFO
Comp: $98.3k
Dr. Andreas Busch Ph.D. (Age 61)
Chief Innovation Officer & Member of Scientific Advisory Board
Comp: $1.56M
Mr. Todd Bedrick CPA
Senior VP & Chief Accounting Officer
Mr. Alexander Khan CPA
VP of Finance & Head of Investor Relations
Ms. Karin Wierinck
Chief People Officer
Melissa Patterson Ph.D.
Chief of Staff
Jens Plassmeier Ph.D.
Senior VP of Biologics Discovery Technology
Mr. Wen Sha
Chief of Staff
Dr. Christine Lemke D.V.M.
M.B.A., Ph.D., Senior Vice President of Portfolio & Growth Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABSI Stock Analysis - Frequently Asked Questions

Should I buy or sell Absci stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Absci in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABSI shares.
View ABSI analyst ratings or view top-rated stocks.
What is Absci's stock price target for 2024?: 4 equities research analysts have issued 12 month target prices for Absci's shares. Their ABSI share price targets range from $7.00 to $13.00. On average, they expect the company's stock price to reach $9.25 in the next year. This suggests a possible upside of 71.9% from the stock's current price.
View analysts price targets for ABSI or view top-rated stocks among Wall Street analysts.
How have ABSI shares performed in 2024?: Absci's stock was trading at $4.20 on January 1st, 2024. Since then, ABSI shares have increased by 28.1% and is now trading at $5.38.
View the best growth stocks for 2024 here.
When is Absci's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ABSI earnings forecast.
How were Absci's earnings last quarter?: Absci Co. (NASDAQ:ABSI) announced its earnings results on Thursday, March, 21st. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.02. The company earned $0.34 million during the quarter, compared to analysts' expectations of $1.75 million. Absci had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 1,933.65%.

What ETF holds Absci's stock?: ARK Genomic Revolution ETF holds 3,164,891 shares of ABSI stock, representing 1.31% of its portfolio.
When did Absci IPO?: Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share.
Who are Absci's major shareholders?: Absci's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Salem Investment Counselors Inc. (0.02%). Insiders that own company stock include Karen K Mcginnis, Redmile Group, Llc, Sarah Korman, Sean Mcclain and Todd Bedrick.
View institutional ownership trends.
How do I buy shares of Absci?: Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABSI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial